Limited Stage Small Cell Lung Cancer

LS-SCLC is typically managed with concurrent chemotherapy and radiation, and based on recent data we now add adjuvant immunotherapy which provides an overall survival benefit. In this talk, we review considerations for radiation dose-fractionation, evidence for addition of immunotherapy, and finally the role of prophylactic cranial irradiation (PCI). This presentation is created purely for educational purposes and does NOT constitute medical advice. If there are any errors or questions/concerns, we welcome comments and discussion!